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Abstract
 
The low number of CD4
 
  
 
CD25
 
  
 
regulatory T cells (T
 
regs
 
), their anergic phenotype, and diverse
antigen specificity present major challenges to harnessing this potent tolerogenic population to
treat autoimmunity and transplant rejection. In this study, we describe a robust method to expand
antigen-specific T
 
regs 
 
from autoimmune-prone nonobese diabetic mice. Purified CD4
 
  
 
CD25
 
 
 
T
 
regs 
 
were expanded up to 200-fold in less than 2 wk in vitro using a combination of anti-CD3,
anti-CD28, and interleukin 2. The expanded T
 
regs 
 
express a classical cell surface phenotype and
function both in vitro and in vivo to suppress effector T cell functions. Most significantly, small
numbers of antigen-specific T
 
regs 
 
can reverse diabetes after disease onset, suggesting a novel
approach to cellular immunotherapy for autoimmunity.
Key words: autoimmunity • tolerance • CD4
 
 
 
CD25
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Introduction
 
It has become increasingly clear that the balance of patho-
genic and immune regulatory pathways underlies disease
progression in many autoimmune settings. The loss of reg-
ulatory pathways such as CTLA-4, TGF-
 
 
 
, and FoxP3
leads to lethal autoimmunity (1–7). This is best exemplified
in type 1 diabetes (T1D) in nonobese diabetic (NOD) mice
and humans, where genetic or biologic loss of function of
these immunoregulatory pathways exacerbates disease devel-
opment (8–10). Increasingly, these pathways have pointed
to a novel CD4
 
  
 
regulatory T cell (T
 
reg
 
) lymphocyte subset
as the central controller of autoimmunity in a variety of ex-
perimental animal models as well as an intrinsic regulator of
spontaneous autoimmunity (for review see references 11–15).
Although the most widely used markers for T
 
regs 
 
are the
expression of CD4 and CD25, other molecules such as
CD62L, CTLA-4, glucocorticoid-induced TNF receptor
(GITR), and FoxP3 have emerged as additional markers of
this unique T cell lineage (5–7, 16–20). Importantly, T
 
reg
 
therapy can effectively delay and cure mice of a variety of
immunological diseases including diabetes, colitis, gastritis,
and graft-versus-host disease (8, 21–24). Several studies
have suggested that the T
 
regs 
 
are antigen specific, relying on
TCR engagement to fully acquire suppressive activity in
vivo
 
.
 
 The regulatory cells appear to function preferentially
at the site of inflammation to effect proliferation and/or
cytokine production by the pathogenic T cells (17, 25, 26).
Recent studies have suggested that T
 
regs 
 
function via the
production of immunosuppressive cytokines, particularly
TGF-
 
  
 
and IL-10 (21, 27–29), whereas other studies indi-
cate that suppressive function requires cell–cell contact and
cannot be attributed to soluble inhibitors (30–36). Barthlott
et al. (37) and Stockinger et al. (38) suggested that T
 
regs
 
function to “take up space,” thus blocking the pathogenic
cells from filling up their appropriate niche. The T
 
reg 
 
popu-
lation is reduced in autoimmune-prone animals and patients
(8, 39). It appears that T
 
regs 
 
may be defective in NOD mice
(8, 39). For instance, T
 
regs 
 
constitute only 
 
 
 
5% of the circu-
lating CD4
 
  
 
T cells in NOD mice, significantly lower than
that observed in other strains (8). Moreover, a large number
of T
 
regs 
 
(1:1 T
 
reg
 
/T
 
eff 
 
ratio) are required to suppress ongoing
disease in this model and other autoimmune models (8, 16,
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17). Finally, recent studies have suggested that it might be
impossible to reverse ongoing autoimmune diabetes due to
the autoreactive T cells becoming resistant to suppression
during the active phase of the disease. However, the studies
were limited to in vitro analyses presumably due to limited
cell numbers (40). In spite of this complexity, the potential
for T
 
regs 
 
to actively regulate autoimmunity and induce long-
term tolerance has great potential applications both for un-
derstanding immune homeostasis and as a strategy for in-
ducing long-lived tolerance.
It has been reported that T
 
regs 
 
preferentially respond to
dendritic cells to proliferate in vitro and in vivo, but the in
vitro T
 
reg 
 
expansion induced by dendritic cells was still very
limited (41). In fact, taking advantage of T
 
regs 
 
has been com-
plicated by the difficulty in expanding and characterizing
this minor T cell subset. In this study, we developed a ro-
bust technique for expanding antigen-specific T
 
regs 
 
from au-
toimmune NOD mice. The expanded T
 
regs 
 
retained all the
quintessential characteristics of this subset including expres-
sion of CD25, CD62L, FoxP3, and GITR. The ability of
expanded NOD T
 
regs 
 
to suppress diabetes in prediabetic and
diabetic mice in vivo was significantly enhanced using the
autoantigen-specific T cells when compared with poly-
clonal T
 
regs
 
. Antigen-specific T
 
regs 
 
effectively suppressed the
development of diabetes in T
 
reg
 
-deficient CD28
 
 
 
/
 
  
 
mice,
blocked syngeneic islet graft rejection in chronically diabetic
animals, and in contrast to previous reports (40), T
 
regs 
 
are
shown to reverse diabetes in mice with new onset disease.
 
Materials and Methods
 
Mice.
 
NOD mice (Taconic), BALB/c mice (Charles River
Laboratories), BDC2.5 TCR transgenic (Tg) mice, glutamic acid
decarboxylase (GAD)286 TCR Tg mice (42), NOD.CD28
 
 
 
/
 
 
 
mice, NOD.RAG
 
 
 
/
 
 
 
 mice, and NOD.TCR-
 
 
 
 
 
/
 
  
 
mice were
housed and bred under specific pathogen-free conditions at the
University of California San Francisco Animal Barrier Facility.
 
Antibodies and Other Reagents.
 
FITC-labeled mAbs against
CD4 (GK1.5) and GITR (DTA-1; reference 19) were purified
from hybridoma culture supernatant and conjugated in our lab.
R-PE–conjugated anti-CD25 (7D4) mAbs were purchased from
Southern Biotechnology Associates, Inc. Allophycocyanin (APC)-
labeled mAbs against CD4 (RM4-5) and CD62L were purchased
from BD Biosciences or eBioscience. The p31/I-A
 
g7
 
mIgG2a was
generated in our lab (43). Carboxyfluorescein diacetate succini-
midyl ester (CFSE) was purchased from Molecular Probes.
 
Cell Sorting and Flow Cytometry.
 
CD4
 
  
 
T cells were enriched
from pooled LNs and spleens by negative selection using an Au-
toMACS (Miltenyi Biotec). The cells were then stained with
anti–CD4-FITC, anti–CD25-PE, and anti–CD62L-APC, and the
T
 
regs 
 
and CD4
 
  
 
CD62L
 
  
 
CD25
 
  
 
T effector cells (T
 
effs
 
) were sorted
on a Mo-Flo cytometer™ (DakoCytomation) based on the ex-
pression of CD4, CD25, and CD62L to 
 
 
 
98% purity. Flow cyto-
metric analyses were performed on a FACScalibur™ flow cytom-
eter with CELLQuest™ software (Becton Dickinson).
 
In Vitro Expansion of T Cells.
 
FACS
 
®
 
-purified T cells were
stimulated with anti-CD3 and anti-CD28 coupled to 4.5-
 
 
 
m
paramagnetic beads (provided by Xcyte Therapeutics Inc.) supple-
mented with 2,000 IU/ml rhIL-2 (Chiron Corp.) in complete
medium, which consisted of 10% heat-inactivated fetal bovine se-
rum (Biosource International), nonessential amino acids, 0.5 mM
sodium pyruvate, 5 mM Hepes, 1 mM glutaMax I (all from Invi-
trogen), and 55 
 
 
 
M 
 
 
 
-mercaptoethanol (Sigma-Aldrich) in
DMEM base. The cultures were monitored daily and maintained
at 0.7–1 
 
  
 
10
 
6
 
/ml by diluting with IL-2–supplemented complete
medium for 8–12 d. At the end of the culture, the anti-CD3 and
anti-CD28 beads were removed using AutoMACS, and the cells
were routinely assayed for CD4, CD62L, and CD25 expression by
flow cytometry and for suppressive activity in vitro. It should be
pointed out that conventional anti-CD3 plus anti-CD28–coated
6-
 
 
 
m polystyrene beads can be adapted for use in this procedure.
 
In Vitro Suppression Assays.
 
Graded numbers of expanded or
fresh sorted T
 
regs 
 
were added to 50,000 CD4
 
  
 
T cells stimulated
with 50,000 irradiated splenic APC (2,000 rads) and 1 
 
 
 
g/ml
anti-CD3 in a U-bottomed 96-well plate. CD4
 
  
 
T cell cultures
without T
 
regs 
 
were stimulated in the same manner as positive con-
trols. For some experiments, CD4
 
  
 
T cells from DO11.10 TCR
Tg mice were used as responders and the cocultures were stimu-
lated with anti-CD3 as described above or with 0.1 
 
 
 
g/ml OVA
peptide. The cultures were maintained at 37
 
 
 
C for a total of 64 or
72 h and pulsed with 1 
 
 
 
Ci/well [
 
3
 
H]thymidine for the last 14 or
8 h, respectively. For some experiments, the responder CD4
 
 
 
cells were labeled with 2.5 
 
 
 
M CFSE before the suppression as-
say, and the level of proliferation was assessed by determining the
dilution of CFSE using flow cytometry 72 h after the initiation of
the culture.
 
Real Time PCR Analysis.
 
Total RNA was extracted using
Trizol reagent (Invitrogen) or RNAeasy (QIAGEN) from ex-
panded T cells. cDNA was synthesized from 50 ng–2.5 
 
 
 
g of each
RNA sample using SuperScript II RNase H reverse transcriptase
and oligo dT as primer (Invitrogen), and 0.6–31.25 ng of the
cDNA was used in each quantitative real time PCR reaction. The
same amount of RNA and cDNA was used for each T
 
reg 
 
and
CD25
 
 
 
 sample pair. Primers and probes for FoxP3, CTLA-4,
neuropilin, PD-1, TRAIL, and HPRT were purchased as reagent
kits from Applied Biosystems. Primer sequences for SOCS-2 were
5
 
 
 
-GCGTCTGGCGAAAGCCCT (forward) and 5
 
 
 
-CTTCAT-
TAACAGTCATACTTCC (reverse), and they were ordered
from Intergrated DNA Technologies Inc. The probe sequence
for SOCS-2 was 5
 
 
 
-FAM-CGCGAGCTCAGTCAAACAGGA-
TGGT-TAMRA-3
 
 
 
, which was ordered from Applied Bio-
systems. The real time PCR was performed on an ABI prizm
7700 using Taqman Universal PCR master mix (Applied Biosys-
tems) in duplicates and the average threshold cycles (Ct) of the
duplicates were used to calculate the fold change between ex-
panded T
 
regs 
 
and CD4
 
  
 
CD62L
 
  
 
CD25
 
  
 
cells. Ct for HPRT was
used to normalize the samples. Expression ratios between T
 
regs 
 
and
CD25
 
  
 
cells were calculated using the following formula: Expres-
sion Ratio (T
 
reg
 
/CD25
 
 
 
)
 
Gene 
 
 
 
 
 
  
 
2
 
n
 
, 
 
n 
 
  
 
(CD25
 
  
 
Ct
 
Gene 
 
 
 
 
CD25
 
  
 
Ct
 
HPRT
 
)
 
   
 
(T
 
reg 
 
Ct
 
Gene 
 
   
 
T
 
reg CtHPRT).
Western Blot. 5   105 of each cell type were lysed in sample
buffer (62.5 mM Tris, pH 6.8, 12.5% glycerol, 2% SDS, 30 ng/
ml bromophenoblue), sonicated, and passed through 28-gauge
needles. The lysates were clarified by centrifugation and boiled
for 5 min before separating on a 10% SDS PAGE gel. The sam-
ples were transferred to PVDF membrane after electrophoresis
and incubated with rabbit anti–FoxP3 antisera (provided by S.
Ziegler, Benaroya Research Institute at Virginia Mason, Seattle,
WA) followed by horseradish peroxidase–conjugated anti–rabbit
Ig. The blot was developed with SuperSignal® Chemilumines-
cent Substrate (Pierce, Rockford, IL) and visualized on a Kodak
Image Station 440CF (Eastman Kodak Co.) and quantified using
Kodak Digital Science 1D Image Analysis software 3.0.Tang et al. 1457
Cytokine ELISA. The level of IL-2, IFN- , IL-10, and
TGF-  in the culture supernatant was determined by ELISA us-
ing antibody pairs purchased from BD Biosciences. For TGF- 
ELISA, the culture supernatant was first treated with acid to
lower the pH to 2.0 to denature latency-associated peptide to al-
low the detection of active TGF- . The supernatant was neutral-
ized to pH 7.0 before ELISA.
Adoptive Transfer. Expanded T cells were labeled with 2.5
 M CFSE, and 1–3   106 cells were transferred via retro-orbital
injection. The recipient mice were killed on day 7 after cell trans-
fer and the dilution of CFSE in splenic, peripheral LN, and pan-
creatic LN cell preparations was determined by flow cytometry.
For adoptive transfer of diabetes to NOD.RAG /  recipients,
CD4  CD62L  CD25  cells from BDC2.5 TCR Tg mice were
purified by cell sorting using a DakoCytomation Mo-Flo and
0.5–1   106 cells were transferred to each recipient mouse. For
some experiments, the purified Teffs were activated with anti-
CD3 and anti-CD28 for 8–10 d before transfer. To transfer dia-
betes with polyclonal Teffs, 25   106 pooled spleen and LN cells
from diabetic NOD mice were injected into each recipient.
When indicated, expanded Tregs were depleted of anti-CD3 and
anti-CD28 beads and washed extensively before mixing with ef-
fector cells for injection. The expanded Tregs were similarly pro-
cessed before transferring into NOD.CD28 / , chronically dia-
betic NOD syngeneic islet transplant recipients, and NOD mice
with new onset diabetes. Nonfasting blood glucose levels in re-
cipient mice were monitored using an Accu-Check glucometer
(Roche Diagnostics Corp.)
Murine Pancreatic Islet Isolation. Murine islets were isolated
using a modified previously published protocol (44). In brief, a
3-ml collagenase P (Roche Molecular Biochemicals) solution
(0.75 mg/ml) was injected into the pancreatic duct of 4-wk-old
NOD mice. The distended pancreases were removed and incu-
bated at 37 C for 17 min. The liberated free islets were purified
by centrifugation on Eurocollin-Ficoll gradients that comprised
four different densities (1.108, 1.096, 1.069, and 1.037). Af-
ter centrifugation, the islet-containing layers between densities
1.069 and 1.096 were collected and washed. Islets were then
handpicked for transplantation.
Murine Islet Transplantation. Naturally diabetic NOD mice
were used as recipients. The mice were diabetic for at least 2 wk
before transplantation. The recipient mice were maintained with
subcutaneous insulin pellets (Lin-Shin Canada, Inc.). 1 d before
transplantation, the insulin pellets were removed and hyperglyce-
mia was confirmed on the day of transplantation. 500 isolated and
handpicked islets were transplanted beneath the left renal capsule
of each recipient. Nonfasting blood glucose levels were deter-
mined in all animals daily after transplantation. Return to nor-
moglycemia within 24 h after transplant was indicative of success-
ful surgery. Rejection of the islets grafts was considered to have
occurred when nonfasting blood glucose concentration exceeded
250 mg/dl for 3 consecutive days.
Results
Expansion of Tregs from Autoantigen-specific TCR Tg NOD
Mice. Previous studies have shown that the number and
function of Tregs in NOD mice decrease over time correlat-
ing with clinical disease onset between 16 and 24 wk of age
(9, 40). These observations support the use of Tregs to pre-
vent or treat diabetes even after disease onset. However,
the ability to use these cells therapeutically is severely lim-
ited by the small numbers of cells resident in the circulation
or lymphoid organs ( 5% of CD4  T cells in NOD mice
and  2% of CD4  T cells in humans with T1D; references
8 and 39). Moreover, a large number of cells are required
for therapeutic efficacy due to an inability at present to se-
Figure 1. In vitro expansion of Tregs. (A) Representative flow cytometry plots of CD25 and CD62L expression on CD4 cells from NOD (left),
BDC2.5 (middle), and GAD286 (right) mice. FACS®-purified Tregs ( ) and CD4  CD62L  CD25  cells ( ) from NOD (B), BDC2.5 TCR Tg (C), or
GAD286 TCR Tg (D) mice were stimulated in vitro with anti-CD3– and anti-CD28–coated beads along with IL-2. (E) T cells from BDC2.5 TCR Tg
mice were expanded as described above with p31-linked IAg7-mIgG2a immobilized on latex beads. All cultures were quantitated by viable cell counting.Expanded Tregs Suppress Diabetes 1458
lect the cells based on antigen specificity. Therefore, we
developed a technique for rapid and efficient expansion of
autoantigen-specific Tregs based on observations that these
cells, present in TCR Tg mice, can be driven into cell cy-
cle with coimmobilized anti-CD3 and anti-CD28 antibod-
ies plus exogenous IL-2. As shown in Fig. 1, A and B,
FACS®-purified NOD Tregs cultured with anti-CD3/anti-
CD28–coated beads in the presence of IL-2 expanded 150–
225-fold in 11 d (Fig. 1 B). In general, the CD4  CD25  T
cells expanded more vigorously (ranging from 300–800-
fold in multiple experiments). A purity of  98% CD4 
CD25  CD62  T cells was essential to enable successful
Treg expansion as a small contamination of either CD25 
CD4  or CD8  T cells significantly impacted the ability to
specifically expand the Tregs (unpublished data). It should be
noted that the Treg expansion is dependent on the high
level of IL-2 (2,000 IU/ml). No Treg expansion was ob-
served when 200 IU/ml IL-2 was used (unpublished data).
Previous studies have shown that CD4  CD25  Tregs iso-
lated from young NOD mice suppressed the ability of Teffs
from diabetic NOD mice to transfer disease in immunode-
ficient NOD mice (8, 16, 17). However, the process was
highly inefficient and the suppressive effects of Tregs in this
setting required a 0.5:1 or 1:1 ratio of Treg/Teff. This is
likely due to the low precursor frequency of antigen-spe-
cific Tregs. Thus, we examined whether Tregs from two dif-
ferent antigen-specific TCR Tg mice (Fig. 1 A) could be
expanded in vitro using the same methodology as with the
polyclonal NOD Tregs. BDC2.5 TCR Tg mice express a
TCR specific for an islet antigen expressed in the granules
of   cells, whereas the GAD286 TCR Tg recognizes a
peptide derived from the islet antigen GAD. Tregs were pu-
rified from BDC2.5 and GAD286 mice and expanded us-
ing the anti-CD3/anti-CD28 plus IL-2 cocktail (Fig. 1, C
and D). The BDC2.5 cells expressed the Tg TCR   
based on efficient staining with an MHC peptide tetramer
previously shown to react with this TCR (43), and the ex-
panded GAD286 Tregs expressed the Tg TCR-  chain (un-
published data). The CD4  CD62L  CD25  and Tregs from
BDC2.5 TCR Tg mice can also be expanded using immo-
bilized MHC peptide dimers (Fig. 1 E). These results sug-
gest that a population of CD4  CD25  CD62L  exists in
both wild-type and TCR Tg mice that can be expanded
using this protocol.
Next, we examined the phenotype of the expanded
Tregs by flow cytometry, Western blot, and real time PCR.
As can be seen in Fig. 2 A, the expanded Tregs maintained
high levels of expression of CD25 as compared with ex-
panded CD25  T cells, whereas the expression of CD62L
remained high in both cell types. In addition, quantitative
PCR showed that all of the Tregs expressed high levels of
SOCS2, PD-1, and CTLA-4 as compared with similarly
expanded CD25  T cells. Moreover, the recently identi-
fied markers neuropilin and TRAIL (20, 45) were also
highly expressed on the expanded Tregs (Fig. 2 B). A high
level of cell surface GITR expression was observed on the
expanded Tregs. However, this previously identified Treg
marker was also induced on the expanded CD25  T cells
(19, 20, and unpublished data). It should be noted that the
quantitative PCR studies were performed on five separate
expanded Treg populations (including both polyclonal and
BDC2.5 TCR Tg Tregs) and the relative expression of the
Treg-specific genes was highly reproducible. Finally, we
examined the recently identified lineage/differentiation
marker for Tregs, FoxP3 (Fig. 2, B and C). As noted by
both real time PCR and Western blot analyses, the ex-
Figure 2. Phenotype of in
vitro–expanded Tregs. (A) Expres-
sion of CD25 and CD62L on ex-
panded Tregs and CD4  CD62L 
CD25  cells was determined by
flow cytometry on day 8 after
the culture initiation. Results are
representative of more than 20
independent experiments. (B)
Levels of mRNA for the indi-
cated genes in expanded NOD
(filled symbols) or BDC2.5 TCR
Tg T cells (open symbols) were
determined by real time PCR
analysis on day 10 after the initia-
tion of the cultures. The relative
expression ratio (Treg/TCD25
 )
for each pair of cultures was cal-
culated from Ct values as described
in Materials and Methods. The
dashed line represents the ratio
of 1 (i.e., identical level of gene
expression in Treg  and CD4 
CD62L   CD25   cultures). (C)
Western blot analysis of FoxP3
protein expression in fresh and expanded T cells. The level of tubulin expression was included as a loading control. Results are representative of three
independent experiments. (D) Cytokine secretion by expanded BDC2.5 T cells 48 h after restimulation with antigenic peptide and splenic APC. Results
are representative of two independent experiments.Tang et al. 1459
panded Tregs expressed levels of FoxP3 similar to those ob-
served in fresh Tregs and significantly higher than those in
fresh or expanded CD25  T cells. The RNA expression
(10-fold) and protein amounts (20-fold) were consistent
with previous studies of fresh Tregs, although there was
clearly some increase in FoxP3 in CD25  Teffs, suggesting
that the culture conditions may induce some Tregs within
the CD25  subset, or FoxP3 is expressed at a low level in
activated Teffs.
We also examined the ability of the expanded Tregs to se-
crete cytokines. Unlike activated CD25  T cells, the Tregs
did not produce IL-2 or IFN- , but rather expressed the
immunosuppressive cytokines IL-10 and TGF-   (Fig. 2
D). Thus, the extensive activation and proliferation of the
Tregs does not alter the phenotype of the Tregs, which re-
mained distinct from the CD25  T cell subset.
Functional Activity of In Vitro–expanded Tregs. Previous
studies have shown that Tregs can effectively suppress prolif-
erative responses of CD25  T cells stimulated with anti-
CD3 and splenic APC. The expanded NOD Tregs effi-
ciently suppressed proliferative responses (Fig. 3 A) and
cytokine production including IL-2 and IFN-  (unpublished
data). In fact, in multiple experiments, the expanded Tregs
suppressed significantly better than fresh NOD Tregs. The
suppression was routinely observed at Treg/Teff ratios of
 1:10. Similar results were observed using the expanded
Tregs from the TCR Tg mice, as the expanded BDC2.5
Tregs were effective in suppressing the proliferative response
of BDC2.5 (unpublished data) as well as polyclonal NOD
T cells (Fig. 3 B). Although the expanded Tregs expressed
significant levels of IL-10 and TGF- , suppressor activity
was unaffected by the addition of anti–IL-10, anti–TGF- ,
or a combination of both antibodies to the in vitro cultures
(unpublished data). These results are consistent with nu-
merous models of Treg suppression where cell–cell contact
is the primary means of immunosuppression in the in vitro
setting (30–36).
To further assess the antigen specificity of the expanded
Tregs and determine whether the expanded Tregs were con-
stitutively suppressive, expanded Tregs from normal BALB/c
mice were examined for their ability to suppress T cells
from the OVA-specific DO11.10 TCR Tg mouse. Tregs
and DO11.10 Tg Teffs were cocultured in the presence of
OVA antigen (to activate only the Teffs) or anti-CD3 (to
activate both the Teff and Tregs). Expanded BALB/c Tregs did
not inhibit the proliferative response of the DO11.10 T
cells stimulated by the OVA peptide. However, the anti-
CD3 response was fully inhibited at low Treg/Teff ratios.
These results suggest that the expanded Tregs lack constitu-
tive suppressive activity but require TCR-specific activa-
tion for effective suppression. This result also ruled out the
trivial possibility that the cells were inhibiting the cultures
by consuming available IL-2 through the high level of
CD25 expression.
In Vivo Survival and Activation of Expanded Tregs. Effec-
tive suppression of immune responses in vivo by Tregs re-
quires that the cells migrate to appropriate sites, respond to
antigen, and survive long-term. We have observed recently
that blockade of the CD28/B7 pathway resulted in rapid
loss of Tregs in vivo and subsequent loss of critical immune
regulation (8, 46). Thus, we examined the ability of ex-
panded Tregs to survive and proliferate in vivo. Expanded
Tregs were labeled with CFSE and transferred into normal
nonlymphopenic syngeneic mice. At 30 d after transfer, the
mice were killed and examined for the number of CFSE 
cells as an indication of cell survival. As seen in Fig. 4 A, a
significant number of CFSE  cells were recovered from
mice transferred with expanded Tregs. The number of
CFSE  Tregs was equal to that observed with fresh Tregs
transferred in the same manner (Fig. 4 A). In fact, Thy1.1-
marked expanded Tregs were observed at least 50 d after
transfer (unpublished data).
Next, we analyzed the ability of the adoptively trans-
ferred Tregs to respond to antigen and proliferate in vivo.
Expanded Tregs from NOD, BDC2.5, and GAD286 mice
were labeled with CFSE and transferred into normal non-
lymphopenic NOD recipients. At 7 d after transfer, the
mice were killed and examined for the dilution of CFSE to
assess in vivo proliferation. As seen in Fig. 4 B, top, a small
but significant number of Tregs proliferated, as indicated by
CFSE dilution. However, there was no selective prolifera-
tion of the NOD Tregs in the pancreatic LNs (Fig. 4 B,
pancLN), suggesting that a detectable number of islet au-
toantigen-specific cells did not exist within the NOD
Treg repertoire. In contrast to the NOD Tregs, Tregs from
BDC2.5 Tg mice proliferated extensively and selectively in
the pancreatic LNs, dividing at least three to four times
during the 7-d period (Fig. 4 B, bottom). Interestingly, the
Figure 3. In vitro suppression by ex-
panded Tregs. (A) Fresh and expanded
Tregs were compared for their ability to
suppress the proliferation of CD4  re-
sponder T cells stimulated with anti-CD3
and T cell–depleted splenocytes. (B) Sup-
pression by Tregs expanded from BDC2.5
TCR Tg or GAD286 TCR Tg mice
was assayed as described in A. (C) Sup-
pressive activity of BALB/c-expanded
Tregs on CD4  responder T cells from
DO11.10 TCR Tg mice stimulated
with anti-CD3 or an OVA peptide.
Results are representative of three inde-
pendent experiments.Expanded Tregs Suppress Diabetes 1460
expression of the CD62L molecule was down-regulated on
the surface of expanded Tregs. This is surprising because the
cells had undergone multiple proliferative cycles in vitro
before transfer and had maintained high levels of CD62L
expression. In contrast to the BDC2.5 Tregs, the GAD286
Tregs did not proliferate in vivo (Fig. 4 B, middle). The re-
sults of previous studies suggest that T cells in these two
TCR Tg mice differ significantly in their thymic develop-
ment. The BDC2.5 Tg mice do not negatively select the
islet-specific T cells in the thymus, but rather develop a
small, reproducible number of Tregs. These cells have been
shown to block disease manifested by potential pathogenic
CD4  CD25  T cells resident in these animals (47). By
comparison, the majority of GAD286 TCR Tg T cells are
deleted in the NOD thymus by negative selection. In fact,
the minor population of cells that escape use alternative
TCR-  chains. Thus, although the peripheral GAD286
TCR Tg cells respond to GAD peptide in vitro, the reac-
tivity is weak and, in contrast to the BDC2.5, they are un-
able to induce diabetes upon adoptive transfer, suggesting
the “absence” of an autoreactive repertoire (42). These re-
sults support the conclusion that the two Tg mice are resis-
tant to diabetes for distinct reasons. The GAD286 TCR Tg
mice are protected from the development of diabetes due
to the potent central tolerance mechanism of clonal dele-
tion and receptor editing. By comparison, the BCD2.5
TCR Tg have circulating autoreactive Tregs that home to
peripheral target tissues where they are activated and ex-
pand after encountering autoantigen, resulting in immune
suppression and homeostasis.
In Vitro–expanded Tregs Suppress Adoptive Transfer of Diabe-
tes In Vivo. Next, we examined the ability of the ex-
panded BDC2.5 Tregs to suppress diabetes after in vivo
cotransfer of activated BDC2.5 T cells into NOD.RAG
mice. The Tregs were effective in blocking the transfer of
diabetes, functioning at as low as a 1:9 ratio of Treg/Teff
(Fig. 5 A), whereas the GAD286 Tregs did not protect even
at a Treg/Teff ratio of 1:1 (Fig. 5 B). In fact, the expanded
BDC2.5 Tregs suppressed polyclonal T cell–mediated dis-
ease. As few as 2   106 expanded BDC2.5 Tregs blocked the
ability of 25   106 diabetogenic NOD spleen and LN cells
to transfer disease (Fig. 5 C). The expanded antigen-spe-
cific Tregs from the BDC2.5 mice were far more efficient
than expanded polyclonal NOD Tregs in preventing the on-
set of diabetes. The same number (2   106) as well as 5  
106 expanded NOD Tregs did not confer any protection un-
der the same conditions (Fig. 5 C). In fact, even the transfer
of four times as many expanded NOD Tregs (8   106) only
slightly delayed diabetes onset and prevented diabetes in
only one diabetogenic cell recipient (Fig. 5 C). This result
is consistent with previous findings suggesting that a high
ratio of polyclonal Tregs to Teffs is necessary to efficiently
suppress disease transfer in this setting (8, 16, 17). Impor-
tantly, these data suggest that in vitro activity of the Tregs
does not predict in vivo function in this disease setting.
Expanded Tregs Prevent Diabetes In Vivo in a Nonlymphopenic
Setting. Although there are multiple models demonstrat-
ing the immunoregulatory activity of Tregs, many of the
systems are based on adoptive transfer models that take ad-
vantage of lymphopenic mice to enhance Treg proliferation
(8, 21–24). Questions have been raised whether disease
suppression observed in lymphopenic settings after Treg
transfer is due to active regulation or a side efffect of com-
petition for “space” (37, 38). Therefore, we examined the
ability of the expanded Tregs to prevent diabetes in a non-
lymphopenic animal model. Previous studies have shown
that CD28 /  NOD mice have normal numbers of T cells
and Th1 responses. In fact, these mice develop exacerbated
Figure 4. In vivo survival and activation of expanded Tregs. (A) Freshly
isolated and expanded BALB/c Tregs were labeled with CFSE and then
injected into normal BALB/c mice (106/mouse). All recipient mice were
killed on day 30 after injection and the numbers of CFSE  cells in the
peripheral LN and spleen (not shown) were determined by flow cytometry.
The data are presented as the number of CD4  CFSE  cells/106 endoge-
nous CD4  T cells. Each circle represents the value from one mouse and
the black bar represents the mean of the group. (B) Expanded Tregs from
NOD.Thy1.2 (top) and GAD286 TCR Tg Thy1.2 (middle) were labeled
with CFSE and 3    106 were transferred to normal 8–12-wk-old
NOD.Thy1.1 recipients. Expanded BDC2.5 TCR Tg Thy1.1 were labeled
with CFSE and 3    106 were transferred to normal 8–12-wk-old
NOD.Thy1.2 recipients. The presence of transferred cells and their activation
status in spleens, LNs, and pancreatic LNs were determined by flow cytome-
try on day 7 after cell transfer. The dot plots shown are gated on the
Thy1.2 for NOD and GAD286 cells and Thy1.1 for BDC2.5 cells. The
percentages of cells with CFSE dilution are shown on the plots. Results
are representative of at least three recipient mice in two separate experiments.Tang et al. 1461
autoimmunity due to a deficiency in Th2 and Tregs, which
were shown to be exquisitely CD28 dependent (8, 21–24).
Thus, we examined whether wild-type expanded BDC2.5
Tregs transferred into CD28 /  NOD mice could delay or
prevent onset of disease. 5   105 Tregs were transferred into
5-wk-old CD28 /  NOD mice and monitored for diabetes
(Fig. 6). The transfer of expanded BDC2.5 Tregs prevented
the development of diabetes in 100% of mice followed for
as long as 20 wk after transfer. In contrast, the transfer of
similar numbers of expanded NOD Tregs had no effect on
disease incidence (unpublished data). These results suggest
that the antigen-specific expanded Tregs functioned in vivo
in the face of a fully functional pathogenic T cell response.
Expanded Tregs Reverse Diabetes In Vivo. The ultimate
utility of Treg therapy depends on an ability to treat individ-
uals with ongoing disease. Thus, we examined the regula-
tory effects of expanded BDC2.5 Tregs in NOD mice that
had been diabetic for at least 2 wk to ensure total endoge-
nous islet cell destruction. Expanded BDC2.5 Tregs were
transferred into diabetic NOD mice in conjunction with
500 syngeneic NOD islet transplant. Mice reverted to nor-
moglycemia within 24–48 h after transplantation. How-
ever, unlike the control mice that rejected the transplanted
islets within 2 wk, the transfer of 2   106 BDC2.5-
expanded Tregs blocked rejection of the syngeneic islets,
consistent with an ability of the suppressor cells to block
ongoing autoimmunity in this setting. The transfer of 5   106
polyclonal NOD Tregs had no effect in this model. More
significantly, the adoptive transfer of expanded BDC2.5
Tregs reversed diabetes in new-onset diabetic NOD mice
(Fig. 7 B). Previous studies have shown that NOD mice di-
agnosed within the first week of hyperglycemia retain suffi-
cient insulin-producing   cell activity, such that effective
immunosuppression introduced at that time can reverse di-
abetes. To test the efficacy of expanded BDC2.5 Tregs in
this setting, 107 Tregs were transferred into NOD mice diag-
nosed with disease based on recently elevated blood glu-
cose levels ( 300 mg/dL). The transferred Tregs reversed
diabetes in 60% of the mice. Thus, the expanded Tregs were
Figure 5. Prevention of diabetes transfer by expanded Tregs. (A) Acti-
vated diabetogenic BDC2.5 CD4  CD62L  CD25  cells (3.5    105)
were cotransferred with BDC2.5-expanded Tregs to 8-wk-old NOD.
RAG /  recipients at the indicated ratio. The blood glucose for in-
dividual recipient mouse was monitored and plotted to access diabetes.
n   3 for no Tregs and 1:9 groups; n   4 for 1:1 and 1:3 groups. Results
are representative of three independent experiments. (B) Diabetes was
induced in 6-wk-old NOD.RAG /  mice in the same manner as described
in A, except that the number of transferred expanded Tregs from GAD286
TCR Tg mice and BDC2.5 TCR Tg mice equaled the number of trans-
ferred Teffs (n   3 mice/group). (C) Diabetes was induced in 5–8-wk-old
NOD.RAG /  or NOD.TCR-  /  recipients by injection of 25   106
pooled spleen and LN cells from diabetic donors (n   8). Some recipient
mice were coinjected with expanded Tregs from NOD (2   106, n   3; 5  
106, n   3; 8   106, n   4) or BDC2.5 TCR Tg mice (2   106, n   4).
Results represent two independent experiments.  Figure 6. Prevention of autoimmune diabetes in NOD.CD28    mice
with BDC2.5-expanded Tregs. 5-wk-old prediabetic NOD.CD28 / 
mice were injected with 5   105 BDC2.5-expanded Tregs (n   3) or left
untreated (n     4). The development of diabetes was monitored and
blood glucose levels of individual mice were plotted. Results are repre-
sentative of at least five independent experiments.Expanded Tregs Suppress Diabetes 1462
extremely effective in blocking and reversing diabetes in an
ongoing autoimmune setting.
Discussion
The past few years have seen an increased interest in and
understanding of the role of Tregs in immune homeostasis.
As an example, we have recently shown that anti-CD3
therapy in new-onset diabetes leads to the production and
expansion of TGF- –dependent Tregs that reverse diabetes
and promote long-term tolerance (9). Moreover, Edinger
et al. (24) have shown that the adoptive transfer of Tregs in
mice can block graft-versus-host disease without affecting
graft-versus-leukemia responses. These studies and others
have led investigators to conclude that these cells might be
involved in human autoimmune diseases. The results have
also prompted investigators to consider this cell type for
immunotherapy. However, successful application of adop-
tive cellular immune therapy with these cells will depend
on a large, reliable source of well-characterized Tregs.
In this study, we describe a robust and effective method
for expanding Tregs while retaining their phenotype and
suppressive activities. We demonstrate that expanded anti-
gen-specific Tregs prevent the development of diabetes and
even restore an immune regulatory state that reverses dia-
betes and allows the mice to maintain long-term immune
homeostasis. The expanded antigen-specific Tregs survived
long-term in vivo, were less dependent on CD28 costimu-
lation (unpublished data), but required antigen exposure for
functional activity. To our knowledge, this is the first ex-
ample of Treg activity in a lymphocyte-sufficient diabetic
animal. These results are especially important in light of a
recent publication by Gregori et al. (40), suggesting that
Tregs do not effectively suppress Teffs in the setting of diabe-
tes. The difference between the two studies may reflect ei-
ther of the different assay systems: in vivo versus in vitro or
that the expanded Tregs might be more efficient. In this re-
gard, we have noted that the expanded Tregs do indeed sur-
vive better in vivo than the fresh Tregs.
Among the more interesting and perhaps unexpected
observations in this study was the differential dependency
of antigen specificity for in vivo versus in vitro Treg func-
tions. Studies in multiple models have shown that poly-
clonal Tregs are effective in blocking autoimmunity (8, 21–
24). In fact, in most settings (with a few notable exceptions
such as allogeneic organ transplantation; reference 28), the
ability to functionally suppress in vitro has been highly pre-
dictive of in vivo efficacy and presumed to be antigen non-
specific. Yet, in this study, the islet autoantigen-specific
BDC2.5 Tregs were significantly more efficient than poly-
clonal NOD Tregs in regulating autoimmune responses in
vivo. This discriminating activity was not predicted by the
in vitro studies that demonstrated equal efficacy in blocking
anti-CD3 responses among the various expanded Tregs.
There are several potential explanations for this observa-
tion. First, it is possible that the expansion method causes
selective depletion of the autoantigen-specific Tregs in the
polyclonal NOD populations. This seems unlikely as the
BDC2.5 Tregs grew in vitro equally well when compared
with the polyclonal NOD Tregs. Moreover, cursory analysis
of the TCR usage in the expanded Tregs showed no prefer-
ential changes in the repertoire of the cells. Second, it is
possible that the different expanded polyclonal Treg popula-
tions homed or functioned differently in vivo. However,
analysis of a panel of cell surface markers, intracellular pro-
teins, and soluble cytokines suggested that the various cell
populations all retained the essential properties of Tregs in-
cluding the high expression of CD25 and FoxP3. Most
likely, the differences observed reflected the model in
which we have tested the Tregs. In many models, Tregs are
cotransferred with effector cells into lymphoid cell–defi-
cient animals, in which the Tregs home to the site of inflam-
mation and inhibit Teff response indirectly by competing for
the “niche.” In fact, in one model of inflammatory bowel
disease (37), CD25  T cells are as effective as CD25  Tregs
with little evidence for antigen specificity. Similarly, there
has been little evidence supporting an essential role for an-
tigen-specific cells for the treatment of graft-versus-host
disease. In sharp contrast, Treg-mediated immune regula-
tion is routinely found to be antigen specific in the non-
Figure 7. Reversal of diabetes with expanded Tregs. (A) NOD mice
with chronic diabetes were transplanted with syngeneic islets under the
kidney capsule. On the day of transplantation, some recipient mice received
5   106 NOD-expanded Tregs (n   4) or 2   106 BDC2.5-expanded Tregs
(n   5), and the remaining mice (n   3) were left untreated. Blood glu-
cose level was monitored. All islet recipients normalized blood glucose
within the first day after transplantation. Results are representative of two
independent experiments. (B) NOD mice with new onset diabetes (blood
glucose   300 mg/dL, n   7) were injected with 107 BDC2.5-expanded
Tregs and blood glucose was monitored. Two consecutive readings of
blood glucose of  250 mg/dL was considered remission of diabetes.Tang et al. 1463
lymphopenic setting (28, 48–50). Thus, the greater func-
tional activity of the antigen-specific Tregs in the NOD
models described herein is most likely due to the fully
functional immune system in these animals and the re-
quirement for effective antigen-mediated reactivation of
Tregs at the inflammatory site.
It is important to note that in the absence of antigen-spe-
cific activation, the Tregs have no effect on regulating dis-
ease. This is most evident in the adoptive transfer studies
using the Tregs isolated from Tg mice on the NOD back-
ground expressing a TCR specific for peptide epitope 286–
300 (p286) of GAD65. Although lymphocytes from these
TCR Tg mice proliferated and produced cytokines when
stimulated in vitro with GAD65 peptide 286–300 (42), the
response was weak and the T cells escaping deletion ex-
pressed alternative TCR-   chains that were unable to
transfer diabetes. In fact, the only model where the GAD
Tg T cells were functional was in an adoptive transfer sys-
tem where the p286-tetramer  CD4  T cells from TCR
Tg mice delayed diabetes induced in NOD.SCID mice by
diabetic NOD spleen cells independent of CD25 expres-
sion, not unlike other systems where the transferred T cells
suppress independent of CD25 expression or antigen-spe-
cific mechanisms (42).
Finally, the observation that the Tregs were able to re-
verse diabetes has important implications for clinical ther-
apy. We imagine a scenario in a number of autoimmune
settings where Tregs are isolated from patients either during
remission (as would be the case for systemic lupus erythe-
matosis or multiple sclerosis) or soon after disease onset (as
would be the case for T1D). The cells would be expanded
and reintroduced at the time of maximal disease activity to
moderate the inflammatory response. In some cases this
could be combined with rapamycin, anti-CD3, or other
drugs that cause deletion of the pathogenic cells without
affecting the Tregs (unpublished data). Together, these ther-
apies could both reduce the short-term pathogenic re-
sponses while reinstating a homeostatic balance for long-
term tolerance induction. Findings in this study suggest
that the efficacy of Treg-based immune therapy is critically
dependent on the antigen specificity of the Tregs, at least in
the autoimmune diabetes setting. Therefore, it is impor-
tant to develop a procedure to selectively and reproducibly
expand antigen-specific Tregs from polyclonal populations
for therapeutic use. Many islet-specific T cell antigens
have been identified to contribute to diabetes develop-
ment in both mice and humans and MHC multimer cou-
pled with these antigenic epitopes has been developed (43,
51–53). It is possible that these MHC multimer reagents
can be adapted for expanding islet-specific Tregs. Current
efforts are underway to identify antigen-specific Tregs in
the polyclonal population and develop a protocol to se-
lectively expand islet antigen–specific Tregs from normal
NOD mice using immobilized antigenic peptide–linked
MHC multimers. In addition, we are developing similar
techniques for purifying and expanding human Tregs for
clinical use in these settings.
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